Company news

Aquestive Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023

Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)

April 19, 2023

Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8: 00 a.m. ET

April 17, 2023

Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets

March 28, 2023

Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

March 6, 2023

Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

February 28, 2023

Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8: 00 a.m. ET

February 21, 2023

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

February 20, 2023

Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives

January 5, 2023

Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

December 21, 2022

Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

November 28, 2022

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting

November 8, 2022

Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

October 31, 2022

Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.

October 26, 2022

Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims

October 23, 2022

Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8: 00 a.m. ET

October 18, 2022

Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film

October 10, 2022

Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets

September 27, 2022

Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®

September 26, 2022

Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board

September 11, 2022

Aquestive Therapeutics to Participate in Two Investor Conferences in September

August 30, 2022

Aquestive Therapeutics Receives FDA Tentative Approval for Libervant™ (diazepam) Buccal Film

August 30, 2022

Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space

August 9, 2022

Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 1, 2022

Aquestive Therapeutics to Participate in Wedbush PacGrow Healthcare Conference

July 25, 2022

Aquestive Therapeutics to Report Second Quarter 2022 Financial Results and Recent Business Highlights on August 2 and Host Conference Call on August 3 at 8: 00 a.m. ET

July 19, 2022

Aquestive Therapeutics Reports Positive Results from Final Two Arms of EPIPHAST Trial Supporting Performance and Real-World Functionality of AQST-109 Epinephrine Oral Film

July 10, 2022

Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

June 14, 2022

Aquestive Therapeutics to Participate in JMP Securities Life Sciences Conference

June 6, 2022

Aquestive Therapeutics, Inc. Announces $8.5 Million Registered Direct Offering

June 5, 2022

Aquestive Therapeutics Announces CEO Transition

May 16, 2022

Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference

May 9, 2022

Aquestive Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 2, 2022

Aquestive Therapeutics to Report First Quarter 2022 Financial Results and Recent Business Highlights on May 3 and Host Conference Call on May 4 at 8: 00 a.m. ET

April 17, 2022

Aquestive Therapeutics Announces Common Stock Purchase Agreement for up to $40 Million with Lincoln Park Capital

April 12, 2022

Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

April 11, 2022

Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis

March 16, 2022

Aquestive Therapeutics Reports Full Year 2021 Results Exceeding Revenue and EBITDA Guidance

March 7, 2022

Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China

March 2, 2022

Aquestive Therapeutics Presented Positive Topline Phase 1 Results for AQST-109 Epinephrine Oral Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

February 27, 2022

Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

February 24, 2022

Aquestive Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film

February 23, 2022

Aquestive Therapeutics to Report Fourth Quarter and Year End 2021 Financial Results and Recent Business Highlights on March 8 and Host Conference Call on March 9 at 8: 00 a.m. ET

February 21, 2022

Aquestive Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

January 6, 2022

Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company’s NDA for Libervant™ (diazepam) Buccal Film

December 19, 2021

Aquestive Therapeutics Added to NASDAQ Biotechnology Index

December 16, 2021

Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Trial (EPIPHAST)

December 12, 2021

Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

November 16, 2021

Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance

November 1, 2021

Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of All...

October 24, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 31 calls. Every call is listed under its year.

Decks

The 5 newest of 59 decks. Every deck is listed under its year.